Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Final Analysis of the ALTTO Trial: Adjuvant Trastuzumab in Sequence or in Combination with Lapatinib in Patients with HER2-positive Early Breast Cancer [BIG 2-06/NCCTG N063D (Alliance)]

E. de Azambuja, M. Piccart-Gebhart, S. Fielding, J. Townend,D. W. Hillman,M. Colleoni,R. Roylance,C. M. Kelly, J. Lombard, S. El-Abed, A. Choudhury,L. Korde, M. Vicente,S. Chumsri, R. Rodeheffer,S. L. Ellard,A. C. Wolff,J. Holtschmidt,I. Lang,M. Untch,F. Boyle,B. Xu,G. Werutsky,J. Tujakowski,C. -S. Huang, N. B. Baruch,J. Bliss,A. Ferro,J. Gralow,S. -B. Kim,J. R. Kroep,I. Krop,S. Kuemmel,R. McConnell,L. Moscetti, A. S. Knop,F. van Duijnhoven,H. Gomez,D. Cameron,S. Di Cosimo,R. D. Gelber,A. Moreno-Aspitia

ESMO OPEN（2024）

Cited 0|Views3
Key words
adjuvant chemotherapy,early breast cancer,HER2-positive,lapatinib,trastuzumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined